Asparaginaza
| Asparaginaza | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Identifikatori | |||||||||
| EC broj | 3.5.1.1 | ||||||||
| CAS broj | 9015-68-3 | ||||||||
| IntEnz | IntEnz view | ||||||||
| BRENDA | BRENDA entry | ||||||||
| ExPASy | NiceZyme view | ||||||||
| KEGG | KEGG entry | ||||||||
| MetaCyc | metabolic pathway | ||||||||
| PRIAM | profile | ||||||||
| PDB | RCSB PDB PDBe PDBj PDBsum | ||||||||
| |||||||||
| Ervinaza | |
|---|---|
| |
| Identifikacija | |
| DrugBank | DB08886 |
| ATC code | L01 |
| Farmakologija | |
| Načini upotrebe | Intramaskularno |
| Vreme polu-uklanjanja iz organizma | 16 h |
|
Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje (25 °C, 100 kPa) materijala | |
| Infobox references | |
Asparaginaza (EC 3.5.1.1, asparaginaza II, L-asparaginaza, kolaspaza, elspar, leunaza, krasnitin, alfa-asparaginaza) je enzim sa sistematskim imenom L-asparagin amidohidrolaza.[1][2][3] Ovaj enzim katalizuje sledeću hemijsku reakciju
- L-asparagin + H2O L-aspartat + NH3
L-asparaginaza je tetramerni enzim koji se sastoji od četiri identične jedinice, svaka od koji ima molekulsku težinu od oko 35 kDa. Ervinaza je antineoplastični agens. FDA je odobrila njenu primenu u novemberu 2011.[4][5][6]
- ↑ Halpern, Y.S. and Grossowicz, N. (1957). „Hydrolysis of amides by extracts from mycobacteria”. Biochem. J. 65: 716-720. PMID 13426090.
- ↑ Ho, P.P.K., Frank, B.H. and Burck, P.J. (1969). „Crystalline L-asparaginase from Escherichia coli B”. Science 165: 510-512. PMID 4894591.
- ↑ Suld, H.M. and Herbut, P.A. (1970). „Guinea pig serum and liver L-asparaginases. Comparison of serum and papain-digested liver L-asparaginases”. J. Biol. Chem. 245: 2797-2801. PMID 4987975.
- ↑ Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, Baruchel A, Goekbuget N, Schrappe M, Pui CH: L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer. 2011 Jan 15;117(2):238-49. doi: 10.1002/cncr.25489. Epub 2010 Sep 7. PMID 20824725
- ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682.
- ↑ David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412.
- Nicholas C. Price, Lewis Stevens (1999). Fundamentals of Enzymology: The Cell and Molecular Biology of Catalytic Proteins (Third izd.). USA: Oxford University Press. ISBN 019850229X.
- Eric J. Toone (2006). Advances in Enzymology and Related Areas of Molecular Biology, Protein Evolution (Volume 75 izd.). Wiley-Interscience. ISBN 0471205036.
- Branden C, Tooze J.. Introduction to Protein Structure. New York, NY: Garland Publishing. ISBN: 0-8153-2305-0.
- Irwin H. Segel. Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems (Book 44 izd.). Wiley Classics Library. ISBN 0471303097.
- Robert A. Copeland (2013). Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists (2nd izd.). Wiley-Interscience. ISBN 111848813X.
- Gerhard Michal, Dietmar Schomburg (2012). Biochemical Pathways: An Atlas of Biochemistry and Molecular Biology (2nd izd.). Wiley. ISBN 0470146842.